Leishmaniasis is a deadly parasitic disease caused by Leishmania spp. And transmitted via sandfly bites. This illness is a globally public health emergency. Different Leishmania species can cause it to manifest in three distinct clinical forms: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). There isn't a registered vaccine against human leishmaniasis right now.
The following antigens have been the subject of intensive research on a number of recombinant subunit vaccine candidates: LeIF, gp63, p36/LACK, A-2, PSA-2/gp46/M-2, FML, LCR1, ORFF, KMP11, LmSTI1, TSA, HASPB1, protein Q, cysteine protease B (CPB), and A (CPA).
Development of Human Leishmania Vaccines
Phase II clinical studies for recombinant antigen vaccines based on LEISH-F1, LIESH-F2, and LEISH-F3 have been completed, indicating their potential as vaccine candidates against leishmaniasis. MPL-SE adjuvanted LEISH-F1 is made up of LEISH-F1 (Leish-111f), an engineered protein encoded by 3 genes: L. major homolog of eukaryotic thiol-specific antioxidant (TSA), stress-inducible protein-1 (LmSTI1), and L. braziliensis elongation and initiation factor (LeIF). LEISH-F2 is derived from LEISH-F1, with an amino acid replacement of glutamine (Gln) for Lys274, which enhances the production process.
GL-SE is an adjuvant present in LEISH-F3, but recombinant nucleoside hydrolase (NH) and sterol 24-c-methyltransferase (SMT) are present separately.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Leishmania Vaccines
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
